Changes in Mf (A and B) CFA (C and D) prevalence at baseline, 1, 2 and 3 years after starting MDA. by Michael C. Payne (2664379)

Subjects:

Comparative analysis of macronutrient compositions between baseline and end of intervention (*p < 0.05, ^ns Non-significant results). by Duc Tran Quang (20564967)

Comparative analysis of caloric intake between baseline and end of intervention (*p < 0.05, ^ns Non-significant results). by Duc Tran Quang (20564967)

Results of RF regression model validation and significance of influencing factors (desert area change and spatiotemporal characteristics of ERI). by Mingyue Sun (4638535)

(a) Average absolute percentage relative error (AAPRE), and, (b) Coefficient of determination (R²) of the models. by Fahd Saeed Alakbari (10701871)

Subjects:

Amplitude for A/L = 0.29. by Muhammad Hammad Bucha (21736111)

“…By increasing the surface roughness of the bluff body, the lock-in region decreases and as a result, the harvested power from that bluff body is reduced. …”

Amplitude for A/L = 0.338. by Muhammad Hammad Bucha (21736111)

“…By increasing the surface roughness of the bluff body, the lock-in region decreases and as a result, the harvested power from that bluff body is reduced. …”

Amplitude for A/L = 0.02. by Muhammad Hammad Bucha (21736111)

“…By increasing the surface roughness of the bluff body, the lock-in region decreases and as a result, the harvested power from that bluff body is reduced. …”

Amplitude for A/L = 0.03. by Muhammad Hammad Bucha (21736111)

“…By increasing the surface roughness of the bluff body, the lock-in region decreases and as a result, the harvested power from that bluff body is reduced. …”

AUC of various models to predict imeglimin efficacy for liver function evaluated by ROC curves. by Naruyoshi Gyoutoku (22537831)

Subjects:

Logistic regression analysis to predict the efficacy for liver function. by Naruyoshi Gyoutoku (22537831)

Subjects:

Comparison in baseline variables between efficacy group and non-efficacy group. by Naruyoshi Gyoutoku (22537831)

Subjects:

Comparison of ALT (A), AST (B), and Fib-4 index (C) before and after imeglimin treatment in ALT ≥ 25 IU/L and ALT < 25IU/L groups. by Naruyoshi Gyoutoku (22537831)

Subjects:

Clinical characteristics at baseline and at the end of the study. by Naruyoshi Gyoutoku (22537831)

Subjects:

Table 1_Dual variants of uncertain significance in a case of hyper-IgM syndrome: implications for diagnosis and management.docx by Nourhen Agrebi (14151222)

“…Background<p>Hyper-IgM syndrome (HIGM) is a genetic immunodeficiency characterized by elevated to normal IgM levels and decreased IgG, IgA, and IgE. …”

Principal Coordinate Analysis (PCoA) based on (A) Unweighted UniFrac, (B) Weighted UniFrac, (C) Bray-Curtis dissimilarity, and (D) Jaccard similarity. by Manal Ali Ahmad (16868808)

Subjects:

Cyclosporin A significantly reduces the survival rate and completely inhibits the formation of multicellular aggregates in tolerant strains under caspofungin stress. by Yongqin Wu (272012)

“…<p>(A) Cyclosporin A decreases the survival rate of tolerant strains under caspofungin. …”

Association between workability and sociodemographic and occupational characteristics. by Sarah A. Bolbol (21702891)

Subjects:

Sociodemographic, occupational, workability characteristics among diabetic workers. by Sarah A. Bolbol (21702891)

Subjects:

Correlation between workability and laboratory findings of diabetic workers. by Sarah A. Bolbol (21702891)

Subjects: